Introduction
============

Lung cancer is a leading cause of death worldwide and imparts a heavy burden on the economies of both more developed and less developed countries. In 2018, 13% of male and female cancer patients were diagnosed with lung cancer for the first time, and the occurrence of lung cancer continues to increase [@B1]. A previous article by the National Lung Screening Trial reported that computed tomography (CT) screening could decrease the mortality associated with lung cancer and strongly supported the use of low-dose helical CT in clinical screenings [@B2].

Pure ground-glass opacity (GGO) nodules are important indicators of lung cancer on CT. GGO nodules are defined as hazy areas, which do not block the parenchymal structures, vessels, and airways under the nodules [@B3], [@B4]. GGO nodules are divided into two categories according to the different solid component percentages: 1) Pure GGO nodules with no solid component within the nodules and 2) Partially solid nodules with both GGO and solid components [@B4]. GGO nodules are not a specific manifestation of lung cancer and can also indicate other lung pathologies such as hemorrhage, inflammation, and fibrosis [@B5]. Several studies have reported that GGO nodules could be closely related to lung cancer prognoses. Moreover, mixed GGO nodules are considered to be more invasive when compared with pure GGO nodules [@B6]-[@B11]. Saji et al. proposed that the only solid nodular components other than whole tumor sizes detected with high-resolution computed tomography were associate with prognoses and malignancies [@B12]. The relationship of GGO nodules with prognoses remains controversial in articles published in the last decade. The association between pure GGO nodules and prognoses has been underreported, and the number of patients with pure GGO nodules in previous retrospective studies was mostly limited. Pure GGO nodules should be given more attention as an important category of GGO nodules.

In this article, we performed a retrospective study to clarify whether pure GGO nodules correlated with prognoses in lung cancer patients. We also analyzed the clinical characteristics of patients with pure GGO nodules to provide information regarding lung cancer diagnoses and treatments for patients in clinical practice.

Methods
=======

Patients
--------

This study was approved by the Ethics Committee of the Provincial Hospital Affiliated with Shandong University, Shandong University, Jinan, China. Every patient in this retrospective study was provided with and read the written informed consent during hospitalization. We reviewed the materials of 1470 patients who had accepted lung cancer resection at our institution between January 2008 and June 2014 and enrolled 1422 patients in this study based on the following criteria: 1) the resected tumor was diagnosed on histopathology as lung cancer; 2) patients had underwent CT scans in our hospital for which a complete diagnostic report was found; 3) patients had a single lesion; 4) patients did not suffer from other malignant cancers except for lung cancer; 5) prior to surgery, patient did not receive other lung surgeries, chemotherapies, or radiotherapies; 6) patients did not have stage Ⅳ lung cancer; and 7) follow-up data were available. To clarify the correlation between pure GGO nodules and prognoses, patients with pure GGO nodules were selected for analysis in our study. We also reviewed materials from 404 patients who had accepted lung cancer resection at our institution between July 2014 and March 2015 to verify our conclusions. The selection criteria were the same as noted for the initial study.

Measurements
------------

The basic information covered in our retrospective study included age, gender, and smoking status of patients collected from the admissions records. Doctors evaluated the possibility of resection according to the tumor stage, which was estimated by chest radiography and physical examination. The status of lymph nodes was determined using histopathologic examination. After the surgeries, patients were followed to get health status information each year until death or lost to follow-up. Once a recurrence and metastasis occurred, CT screening frequencies changed from every year to every half year. All CT images were read by more than two experienced doctors independently. Nodules were repeatedly measured to acquire the average diameters.

Statistical Analysis
--------------------

In this retrospective study, we used the Kaplan-Meier method to estimate the overall survival (OS) and progression-free survival (PFS) curves and used the log-rank test to make comparisons. Hazard ratios (HRs), 95% confidence intervals (CIs) were performed, and Cox regression analyses were used to determine if the clinical variables were prognostically significant. A two-sided p-value \<0.05 indicated that a variable was prognostically significant. All data were analyzed by SPSS software (version 19, SPSS Inc., Chicago, IL, USA).

Compared with other lung cancer patients in our study, the number of patients with pure GGO nodules was still relatively small. To comprehensively analyze the prognostic significance of pure GGO nodules, we performed individual matching (1:2) by size and stage, respectively. For the size-matching group, the matching characteristics were size, age, gender, and smoking status. For the stage-matching group, the matching characteristics were tumor stage, age, gender, and smoking status. We also performed multivariate analyses on data from matched pairs of 41 patients with pure GGO nodules and 82 patients without pure GGO nodules. Moreover, subgroup analysis was also an important part of our study. We divided the enrolled patients into subgroups according to their smoking status, gender, age, pathologic diagnosis. The Kaplan-Meier method was used to study the influence of the subgroups on prognoses.

Results
=======

Pure GGO nodules were associated with no-smoking females with adenocarcinoma
----------------------------------------------------------------------------

We divided 1422 lung cancer patients who received surgery at our hospital into two groups according to whether patients had pure GGO nodules. After surgery, the median follow-up period was 45.0 months (1-100). Table [1](#T1){ref-type="table"} shows the clinical characteristics of 39 lung cancer patients with pure GGO nodules and 1383 patients without pure GGO nodules. There was no significant difference between the two groups for age (p=0.197). While we revealed that non-pure GGO nodules were associated with males (p=0.001), smoking (p\<0.001), and lymph node metastases (p\<0.001), we also found that most pure GGO nodules were diagnosed at earlier stage (p\<0.001) and the size of nodules was smaller (p\<0.001) than the other nodule types. Most pure GGO nodules were confirmed to be well-differentiated as pathologically diagnosed (p\<0.001). And adenocarcinoma is the most common histology among patients with pure GGO nodules (p\<0.001). Only one case in our study was found lymph node metastasis.

Pure GGO nodules were associated with a better prognosis compared with non-pure GGO nodules
-------------------------------------------------------------------------------------------

Figure [1](#F1){ref-type="fig"} shows the survival curves of the two groups. Kaplan-Meier analysis demonstrated that pure GGO nodules were significantly associated with longer PFS (p=0.046) and OS (p=0.037) in lung cancer patients, which was similar to that seen with our verification process [supplementary figure 1](#SM0){ref-type="supplementary-material"}A-B), and the clinical information was shown in [Supplementary Table 1](#SM0){ref-type="supplementary-material"}. To show the effect of pure GGO nodules on OS and PFS more clearly, we performed univariate analysis of common clinicopathologic factors for prognosis. Results in Table [2](#T2){ref-type="table"} showed smaller tumor sizes, less invasion into lymph nodes, more-differentiated tumors, and earlier stages at diagnosis were favorable predictors for PFS in lung cancer patients. A multivariate Cox model that adjusted for the pure GGO nodules, tumor sizes, lymph node invasiveness, and tumor grades and stages was performed. Our results showed that the size (HR=1.281, 95%CI 1.051-1.562, p=0.014), lymph node metastatic rate (HR=1.670, 95%CI 1.299-2.146, p\<0.001), tumor grade (p=0.001), tumor stage (p=0.006) were independent prognostic factor for OS.

There were no significant differences in the prognoses of patients with pure GGO nodules compared with those with non-pure GGO nodules regarding tumor stage matching analyses
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In the stage matching group, clinical characteristics of the pure GGO nodule group and the non-pure GGO nodule group were similar, as shown in Table [3](#T3){ref-type="table"}. Kaplan-Meier analyses showed that no significant differences in patient prognoses were observed in patients with pure GGO nodules compared with those that had non-pure GGO nodules (Figure [2](#F2){ref-type="fig"}. In the subgroup analyses, the age and gender subgroups showed no differences between the pure GGO nodule and non-pure GGO nodule groups for prognoses.

In our verification process, results were different, Kaplan-Meier analyses showed that there were no significant differences in the OS (p=0.375, [supplementary figure 1](#SM0){ref-type="supplementary-material"}D) of patients with pure GGO nodules and those with non-pure GGO nodules. Regarding PFS, we found that patients with pure GGO nodules achieved a longer PFS (p=0.016, [supplementary figure 1](#SM0){ref-type="supplementary-material"}C). The clinical information was shown in [Supplementary Table 2](#SM0){ref-type="supplementary-material"}. These two results could be caused by different follow-up times. In the stage matching group, the pure GGO nodule group had a higher PFS during short-term follow-up, but there was no significant difference in OS.

Non-smoking female patients with lung cancer were more likely to have adenocarcinoma
------------------------------------------------------------------------------------

Figure [3](#F3){ref-type="fig"}A-B showed that in the non-smoking subgroup, patient prognoses in pure GGO nodule group was better than those in the non-pure GGO nodule group. In the female patient subgroup, the PFS of patients with non-pure GGO nodules was shorter compared with those with pure GGO nodules (p=0.029, Figure [4](#F4){ref-type="fig"}A-B). Among the female non-smoking subgroup, the histology of pure GGO nodules and non-pure GGO nodules was similar, and most of those patients were diagnosed as adenocarcinoma. However, in this subgroup, most pure GGO nodules were diagnosed at earlier stages (p\<0.001), had a lower pathologic grade (p\<0.001), smaller nodules (p=0.006), and no lymph node metastases compared with the non-pure GGO nodules.

Discussion
==========

GGO nodules are an important CT manifestation found in clinical practice. Pure GGO nodules were thought to indicate well-differentiated lung tumors and predict good prognoses in some previous case reports. In our study, most of pure GGO nodules were found in the early stages of the disease, and there was less lymph node invasion compared with other lung cancer nodules. The prognoses were similar between lung cancer patients with pure and non-pure GGO nodules, as previously reported. It has been shown that pure GGO nodules took longer to double in size compared with mixed GGO nodules and solid nodules [@B13], [@B14]. Park et al. reported no recurrences or metastases after 24 months in a patient who had a pure GGO nodule resected. There was also no significant difference in the prognoses in terms of tumor size [@B15]. However, our study showed that tumor size played an important role in prognoses. Because most lung cancer patients with pure GGO nodules were in earlier disease stages, and had smaller tumor sizes compared with those without pure GGO nodule, both earlier disease stages and smaller tumor sizes are thought to predict a better prognosis as reported in a previous article [@B16]. Therefore, follow-up periods should be longer when wanting to clarify the correlation between pure GGO nodules and prognosis. The follow-up time in our study was 100 months, which was five times longer than that of the study by Park et al.

Takatoshi Aoki reported that about 10-25% of pure GGO nodules increase in size or gradually become solid nodules [@B17]. Although, there was a published article which described invasiveness and malignant potential of pulmonary lesions presenting as pure GGO nodules and reported 12% of examined patients with pure GGO were diagnosed as invasive cancers. Besides, it was commonly considered that the pure GGO nodules were more stable than those with mixed GGO nodules [@B18]. However, our results showed that prognosis of patients with pure GGO nodules was not as good as we had expected in the long-term follow-up stage matching study; there was no significant difference in the tumor stages between pure GGO nodule group and non-pure GGO nodule group. While at the short-term follow-up visits, the pure GGO nodule group had a higher PFS. Although there was no difference in long-term prognoses in the stage matching study, in the short-term, the pure GGO nodule group had a longer PFS compared with the non-pure GGO nodule group. One hypothesis was that GGO nodules were not specific signs for lung cancer. The opacity in the CT images increased because cells and fluid-filled part of alveolar lumen and air was partially decreased [@B4]. Thus GGO nodules also can indicate another lung disease such as inflammation, fibrosis, and edema [@B13]. Inflammation was also thought to play an important role in the occurrence and development of tumors. Some markers of inflammation were confirmed to be associated with poor prognoses [@B19]. In addition to these diseases, some GGO nodules were in unstable, which can lead to a worse prognosis. Mao et al. reported no differences were seen between the lesions that were not invasive and those that were invasive regarding shape, size, and window when the Pearson X^2^ test was used for analysis. It is still hard to distinguish the malignant nodules and well-differentiated nodules by size on CT image[@B20].

The female non-smoking subgroup was the most concerning of the two subgroups in our study. Oh et al. reported that during a follow-up period, female patients with GGO nodules were at a greater risk of having a poor prognosis compared with those that did not have GGO nodules [@B21]. Most malignant GGO nodules were diagnosed as adenocarcinoma as previous articles reported [@B22]-[@B24]. Adenocarcinoma also accounts for a large percentage of lung tumors in female patients [@B25]. The facts mentioned above can explain why pure GGO nodules indicate good prognoses in female patients as opposed to male patients. Smoking status is the dominant factor influencing prognosis in the univariate analysis of our study. An interesting caveat is that in the non-smoking subgroup, the prognosis of patients with pure GGOs significantly differed from that of patients without pure GGO nodules. A retrospective study looked at 5-year survival in non-smoking lung cancer patients compared with smokers and found that smoking was a predictor of an unfavorable prognosis. Although the mechanisms of how smoking influenced the prognosis of lung patients were not clear, some hypotheses were formed. Smoking was shown to impair both local and systematic immunity by reducing the actions of T and B lymphocytes, and NK cells. Moreover, smoking also can also cause peripheral blood leukocytosis [@B26].

There were some limitations in our study. First, because our study was retrospective, an inherent bias was unavoidable. Future prospective studies should be considered, and patient characteristics should be considered to create detailed projects that can minimize bias. Second, the number of patients with pure GGO nodules in our study was small because of the relatively low use of CT screening in the past few decades. Meanwhile, the incidence of pure GGO nodules was reasonably low when compared with solid nodules. Therefore, larger studies are warranted in the future.

In conclusion, as a subgroup of GGO nodules, pure GGO nodules predict a better prognosis in lung cancer patients. For the first time, we showed that when comparing lung patients with similar stage nodules, although there was no difference in long-term prognoses, in the short term, patients with pure GGO nodules had longer PFS. In clinical practice, it is important to consider the correlation between pure GGO nodules and improved prognoses.
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![**(A)** The Kaplan-Meier survival curve for PFS between 41 patients with pure GGO nodules and 1390 patients with other lung cancer nodules after surgery (P-value = 0.046).**(B)** The Kaplan-Meier survival curve for OS between 41 patients with pure GGO nodules and 1390 patients with other lung cancer nodules after surgery (P-value = 0.037).](jcav10p6888g001){#F1}

![**(A)** The Kaplan-Meier survival curve for PFS between 41 patients with pure GGO nodules and 82 patients with matching tumors stages after surgery (P value is 0.848). **(B)** The Kaplan-Meier survival curve for OS between 41 patients with pure GGO nodules and 82 patients with matching tumor stages after surgery (P-value is 0.103).](jcav10p6888g002){#F2}

![**(A)** The Kaplan-Meier survival curve for PFS between patients with pure GGO nodules and patients with other lung cancer nodules after surgery in the non-smoking subgroup (P-value = 0.017). **(B)** The Kaplan-Meier survival curve for OS between patients with pure GGO nodules and patients with other lung cancer nodules after surgery in the non-smoking subgroup (P-value = 0.022).](jcav10p6888g003){#F3}

![**(A)** The Kaplan-Meier survival curve for PFS between patients with pure GGO nodules and patients with other lung cancer nodules after surgery in the female subgroup (P value = 0.029). **(B)** The Kaplan-Meier survival curve for OS between patients with pure GGO nodules and patients with other lung cancer nodules after surgery in the female subgroup (P value = 0.076).](jcav10p6888g004){#F4}

###### 

The association of pure GGO nodules with the clinicopathologic characteristics of 1422 patients with lung cancer and treated with surgery.

  Characteristic                     Total, n=1422   Non-pure GGO nodule, n=1383   Pure GGO nodule, n=39   p-value
  ---------------------------------- --------------- ----------------------------- ----------------------- ---------
  **Gender, n (%)**                                                                                        
  Male                               999 (70.3)      981 (70.9)                    18 (46.2)               0.001
  Female                             423 (29.7)      402 (29.1)                    21 (53.8)               
  **Age, years**                                                                                           
  ≤60                                767 (53.9)      742 (53.7)                    25 (64.1)               0.197
  \>60                               655 (46.1)      641 (46.3)                    14 (35.9)               
  **Smoking history, n (%)**                                                                               
  Never                              518 (36.4)      492 (33.5)                    26 (66.7)               \<0.001
  Former                             178 (12.5)      175 (12.6)                    3 (7.7)                 
  Current                            726 (51.0)      716 (51.7)                    10 (25.6)               
  **Histology, n (%)**                                                                                     
  Adenocarcinoma                     697 (49.0)      663 (47.9)                    34 (87.1)               \<0.001
  Squamous                           519 (36.5)      519 (37.5)                    1(2.6)                  
  SCLC                               109 (7.7)       109 (7.9)                     0 (0)                   
  Other                              97 (6.8)        92 (6.7)                      4(10.3)                 
  **Tumor size, n (%)**                                                                                    
  ≤3cm                               663 (46.6)      635 (45.9)                    34 (87.2)               \<0.001
  \>3cm                              759 (53.3)      748 (54.1)                    5 (12.8)                
  **Lymph node metastasis, n (%)**                                                                         
  No                                 771 (54.2)      734(53.1)                     37 (94.9)               \<0.001
  Yes                                651 (45.8)      649(46.9)                     2 (5.1)                 
  **Pathological grade, n (%)**                                                                            
  Well                               169 (11.9)      143 (10.3)                    26 (66.7)               \<0.001
  Moderately                         645 (45.4)      642 (46.4)                    3 (7.7)                 
  Poorly                             493 (34.6)      491 (35.6)                    2 (5.1)                 
  Unknown                            115 (8.1)       107 (7.7)                     8 (20.5)                
  **Pathological stage, n (%)**                                                                            
  I                                  566 (39.8)      533 (38.5)                    33 (84.6)               \<0.001
  II                                 392 (27.6)      388 (28.1)                    4 (10.3)                
  III                                464 (32.6)      462 (33.4)                    2 (5.1)                 

SD standard deviation; SCLC small cell lung cancer; GGO ground glass opacity.

###### 

Univariate and multivariate analyses of prognostic factors for OS and PFS.

                               OS                    PFS                                                                                             
  ---------------------------- --------------------- --------- --------------------- --------- --------------------- --------- --------------------- ---------
  **Pure GGO nodules**                                                                                                                               
  No                           1                               1                               1                               \*                    \*
  Yes                          0.464 (0.220-0.977)   0.043     1.417 (0.649-3.094)   0.381     0.451 (0.202-1.010)   0.053     \*                    \*
  **Age**                                                                                                                                            
  ≤60                          1                               1                               1                               \*                    \*
  \>60                         1.241 (1.052-1.463)   0.010     1.372 (1.158-1.624)   \<0.001   1.034 (0.860-1.244)   0.722     \*                    \*
  **Gender**                                                                                                                                         
  Female                       0.744 (0.616-0.899)   0.002     1.148 (0.876-1.504)   0.317     1.182 (0.964-1.449)   0.109     \*                    \*
  Male                         1                               1                               1                               \*                    \*
  **Histological subtype**                                                                                                                           
  Adenocarcinoma               1                               1                               1                               \*                    \*
  Squamous                     1.156 (0.965-1.385)   0.115     0.801 (0.655-0.979)   0.031     0.871 (0.711-1.068)   0.184     \*                    \*
  SCLC                         1.598 (1.197-2.133)   0.001     0.838 (0.612-1.148)   0.270     1.137 (0.807-1.601)   0.463     \*                    \*
  Others                       0.993 (0.698-1.414)   0.045     1.081 (0.656-1.780)   0.760     0.776 (0.514-1.172)   0.228     \*                    \*
  **Smoking index**                                                                                                                                  
  Never                        1                               1                               1                               \*                    \*
  Former                       1.512 (1.167-1.960)   0.002     1.121 (0.805-1.561)   0.500     1.306 (0.981-1.738)   0.067     \*                    \*
  Current                      1.66 (1.134-1.645)    0.001     1.007 (0.772-1.314)   0.959     1.053 (0.861-1.288)   0.615     \*                    \*
  **Tumor size**                                                                                                                                     
  ≤3cm                         1                               1                               1                               1                     
  \>3cm                        1.909 (1.606-2.269)   \<0.001   1.281 (1.051-1.562)   0.014     1.758 (1.452-2.128)   \<0.001   1.278 (1.029-1.578)   0.027
  **Lymph node metastasis**                                                                                                                          
  No                           1                               1                               1                               1                     
  Yes                          2.904 (2.442-3.455)   \<0.001   1.670 (1.299-2.146)   \<0.001   2.297 (1.901-2.774)   \<0.001   1.428 (1.082-1.884)   0.012
  **Pathological TMN stage**                                                                                                                         
  Ⅰ                            1                               1                               1                               1                     
  II                           2.416 (1.907-3.060)   \<0.001   1.541 (1.135-2.090)   0.006     2.035 (1.587-2.610)   \<0.001   1.345 (0.969-1.865)   0.076
  III                          4.219 (3.396-5.241)   \<0.001   2.264 (1.615-3.174)   \<0.001   3.063 (2.431-3.860)   \<0.001   1.759 (1.217-2.543)   \<0.001
  **Differential degree**                                                                                                                            
  Well                         1                               1                               1                               1                     
  Moderate                     3.420 (2.215-5.280)   \<0.001   2.220 (1.406-3.505)   0.001     2.197 (1.480-3.261)   \<0.001   1.524 (1.017-2.286)   0.041
  Poor                         4.302 (2.777-6.663)   \<0.001   2.514 (1.580-4.002)   \<0.001   3.039 (2.044-4.519)   \<0.001   1.934 (1.282-2.917)   0.002
  Unknown                      2.527 (1.497-4.264)   0.001     1.843 (0.986-3.444)   0.055     1.641 (0.976-2.759)   0.062     1.346 (0.798-2.269)   0.226

Abbreviation: OS= overall survival; PFS=progression-free survival; HR=hazard ratio; CI=confidence interval; SCLC=small cell lung cancer.

###### 

The association of pure GGO nodules with the clinicopathologic characteristics of 117 patients with individual-matching according to tumor stage.

  Characteristic                     Total, n=117   Non-pure GGO nodule, n=78   Pure GGO nodule, n=39   p-value
  ---------------------------------- -------------- --------------------------- ----------------------- ---------
  **Gender, n (%)**                                                                                     
  Male                               54 (46.2)      36 (46.2)                   18 (46.2)               1.000
  Female                             63 (53.8)      42 (53.8)                   21 (53.8)               
  **Age, years**                                                                                        
  ≤60                                77 (65.8)      52 (66.7)                   25 (64.1)               0.783
  \>60                               40 (34.2)      26 (33.3)                   14 (35.9)               
  **Smoking history, n (%)**                                                                            
  Never                              79 (67.5)      53 (67.9)                   26 (66.7)               0.664
  Former                             6 (5.1)        3 (3.8)                     3 (7.7)                 
  Current                            32 (27.4)      22 (28.2)                   10 (25.6)               
  **Histology, n (%)**                                                                                  
  Adenocarcinoma                     102(87.2)      68 (87.2)                   34 (87.2)               1.000
  Squamous                           3(2.6)         2(2.6)                      1(2.6)                  
  SCLC                               0 (0.0)        0 (0.0)                     0 (0)                   
  Other                              12 (10.2)      8 (10.2)                    4(10.2)                 
  **Tumor size, n (%)**                                                                                 
  ≤3cm                               96 (82.1)      62 (79.5)                   34 (87.2)               0.307
  \>3cm                              21 (17.9)      16 (10.5)                   5 (12.8)                
  **Lymph node metastasis, n (%)**                                                                      
  No                                 106 (90.6)     69 (88.5)                   38 (97.4)               0.102
  Yes                                11 (9.4)       9 (11.5)                    1 (2.6)                 
  **Pathological grade, n (%)**                                                                         
  Well                               46 (39.3)      20 (25.6)                   26 (66.7)               \<0.001
  Moderately                         34 (29.1)      31 (39.7)                   3 (7.7)                 
  Poorly                             13 (11.1)      11 (14.1)                   2 (5.1)                 
  Unknown                            24 (20.5)      16(20.5)                    8 (20.5)                
  **Pathological stage, n (%)**                                                                         
  I                                  99 (84.6)      66(84.6)                    33 (84.6)               1.000
  II                                 12 (10.3)      8 (10.3)                    4 (10.3)                
  III                                6 (5.1)        4 (5.1)                     2 (5.1)                 

SD standard deviation; SCLC small cell lung cancer; GGO ground glass opacity.

###### 

The association of pure GGO nodules with the clinicopathologic characteristics of 380 non-smoking female patients.

  Characteristic                     Total, n=380   No pure GGO nodule, n=361   Pure GGO nodule, n=19   p-value
  ---------------------------------- -------------- --------------------------- ----------------------- -----------
  **Age, years**                                                                                        
  ≤60                                235 (61.8)     223 (61.8)                  12 (63.2)               0.904
  \>60                               145 (38.2)     138 (38.2)                  7 (36.8)                
  **Histology, n (%)**                                                                                  
  Adenocarcinoma                     301 (79.2)     285 (78.9)                  16 (84.2)               0.764
  Squamous                           30 (7.9)       30 (8.3)                    0(0.0)                  
  SCLC                               23 (6.1)       23 (6.3)                    0(0.0)                  
  Other                              26 (6.8)       23 (6.3)                    3(15.8)                 
  **Tumor size, n (%)**                                                                                 
  ≤3cm                               226(59.5)      209 (57.9)                  17(89.5)                **0.006**
  \>3cm                              154 (40.5)     152 (42.1)                  2 (10.5)                
  **Lymph node metastasis, n (%)**                                                                      
  No                                 217 (57.1)     198 (54.8)                  19(100.0)               **0.000**
  Yes                                163 (42.9)     163 (45.2)                  0 (0.0)                 
  **Pathological grade, n (%)**                                                                         
  Well                               86 (22.6)      73(20.2)                    13 (68.4)               **0.000**
  Moderately                         138 (36.3)     137 (37.9)                  1 (5.3)                 
  Poorly                             115 (30.3)     115 (31.9)                  0(0.0)                  
  Unknown                            41(10.8)       36(10.0)                    5 (26.3)                
  **Pathological stage, n (%)**                                                                         
  I                                  184 (48.4)     168 (46.5)                  16 (84.2)               **0.001**
  II                                 83(21.8)       81(22.4)                    2 (10.5)                
  III                                113 (29.7)     112 (31.0)                  1(5.3)                  
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